What this decision does and does not settle

Federal and accreditation requirements govern specimen identification, integrity, procedure manuals, records, and preanalytic quality assessment, and peer-reviewed guidance covers hemolysis interference and detection. The pattern of the decision is identity and irreversibility first, then correctability, then urgency, then a documented disposition; there is no universal cutoff for hemolysis, lipemia, icterus, delay, temperature, or minimum volume, because none exists across laboratories, analyzers, and assays.

Recollection risk and clinical urgency are real inputs to the decision, but they never erase an identity requirement, a safety concern, a method limitation, or a documentation requirement. An approved exception is not a way around those requirements; it is a documented, authorized path that still ends with the limitation stated in the report.

Acceptance under exception does not establish clinical validity. The laboratory releases the result and the stated limitation supported by its own procedure and the underlying method evidence, and nothing more; what the result means for the patient remains a clinical judgment made with that limitation in view.

CLIA-required quality assessment expects the laboratory to monitor and evaluate preanalytic problems over time, not just resolve them one specimen at a time, so repeated rejection categories such as hemolysis, clots, quantity-not-sufficient, or transport excursions get tracked.

The four-question screen tells you where to look; the laboratory's own current procedure tells you what to do when you get there.